We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug News
    • Trending
    • Commercial Operations
    • GMPs
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Drug Weekly
    • FDAnews
  • Device News
    • Trending
    • Commercial Operations
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Device Weekly
    • FDAnews
  • Books
    • FDAnews Books Library
    • Drug Books
    • Device Books
  • Training/Events
    • Webinar Training Pass
    • Events
  • Resources
    • Form 483s Database
    • FDA Approved Drugs
    • White Papers
  • CenterWatch
  • About Us
    • The Company
    • FDAnews Editorial Board
    • Contact Us
  • Advertising
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Indian Hospira Plant Gets Form 483 With 23 Observations

Indian Hospira Plant Gets Form 483 With 23 Observations

December 27, 2013

Long-embattled sterile injectables maker Hospira was hit with a new Form 483 containing nearly two dozen observations after FDA investigators followed up an October 2012 inspection that uncovered inadequate sanitization procedures at its Irungattukottai, India, manufacturing plant.

Hospira promised in May to address the FDA’s concerns about its plant, as well as to create the global corrective action plan mandated in the warning letter that followed the 2012 inspection.

The observations listed in the fresh Form 483 relate mainly to processes and procedures, according to an SEC filing. Hospira says it takes this matter seriously and intends to respond fully in the coming weeks. A disruption in production is not anticipated, the drugmaker adds.

In the wake of those revelations comes more bad news from Hospira as it now finds itself recalling one lot of certain single-dose vials of lidocaine HCl injection, USP, according to an FDA safety alert published Dec. 23. The market correction was prompted due to a reddish-orange particulate on the inner surface of the vials and inside the solution itself, the agency says.

Hospira has a history of struggling with particulates in its products. Most recently, a July-to-August inspection of its McPherson, Kan., plant turned up glass in sterile lyophilized drugs.

But more than three years after Hospira’s Rocky Mount, N.C., plant was warned for lax quality control, prompting a painful manufacturing slowdown and a costly remediation, the drugmaker expects to near the “top end” of production capability in 2014, Hospira’s chief said last month.

Company-wide remediation efforts have cost the generic injectable drugmaker $458 million since it was first warned by the FDA in 2010 for particulate contamination problems. Since then, it has struggled with shortages as it labored to maintain scaled-back production under the scrutiny of third-party auditors. — Lena Freund

Drugs GMPs Inspections and Audits Quality Regulatory Affairs

    Upcoming Events

    • 28Sep

      The Cost of Counterfeiting: Why You Need a Plan to Secure Your Medical Device Supply Chain

    • 28Sep

      Calculating Sample Size to Satisfy FDA Expectations

    • 11Oct

      GMP Quality Management vSummit 2023: Where Quality Meets Risk

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    • 02Nov

      How UDI and UDI Data Can — and Must — Be Used for More Than Just Device Identification

    Featured Products

    • FDA, FTC and DOJ Enforcement of Medical Device Regulations

      FDA, FTC and DOJ Enforcement of Medical Device Regulations

    • Using Real-World Evidence in Drug and Device Submissions

      Using Real-World Evidence in Drug and Device Submissions

    Featured Stories

    • Expert Says FDA Under No Obligation to Educate Companies on Inspection Rights

    • FDA Deems Hamilton Ventilator Recall Class I for Software Issue Causing Device to Stop

    • Survey Shows Nearly All Pharm Techs Face Drug Shortages, Pfizer Plant Shortages Continue Until 2024

    • FDA Shares Premarket Requirements for Device Cybersecurity in Final Guidance

    The Revised ICH E8: A Guide to New Clinical Trial Requirements

    Learn More
    • Drug Products
      • Quality
      • Regulatory Affairs
      • GMPs
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Device Products
      • Quality
      • Regulatory Affairs
      • QSR
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Clinical Products
      • Trial Design
      • Data Integrity
      • GCP
      • Inspections and Audits
      • Transparency
    • Privacy Policy
    • Do Not Sell or Share My Data
    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing